好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of Seizure Control and Neuropathology in Dementia
Aging, Dementia, and Behavioral Neurology
S1 - Innovations in Non-AD Dementia (2:48 PM-3:00 PM)
010

Seizures in people with dementia (PWD) are linked to faster cognitive decline, but the effects of ongoing seizures on postmortem neuropathological changes remain unclear.

The study objective was to explore the impact of active versus remote seizures on postmortem findings in PWD, using data from 39 Alzheimer’s disease centers in the US, collected from September 2005 to December 2021.

Participants with all-cause dementia were classified into three groups: active seizures (within the past year), remote seizures (previous but not recent), and no seizures (controls). The differences in baseline demographics, mortality rates, and postmortem findings were analyzed using Pearson’s Chi-squared test, Fisher’s exact test, t-test, and ANOVA.

Among the 10,474 deceased participants, those with active seizures had the highest mortality (active=56%, remote=35%, controls=34%, p<0.001). Autopsies were performed on 6,085 participants (58.1% of the deceased), including 294 with active seizures, 151 with remote seizures, and 5,640 controls. The groups differed by age at death (active=75.8 years, remote=77.9 years, controls=80.8 years, p<0.001) and dementia severity (CDR-Global: active=2.36, remote=1.90, controls=1.69, p<0.001), but had no differences in education, sex, or race. Post hoc analyses revealed that PWD with active seizures had more severe Alzheimer’s disease pathology, including higher Braak stages and denser neocortical neuritic plaques, compared to remote seizure participants and controls. Active seizure participants also showed greater cerebral and hippocampal atrophy and locus coeruleus hypopigmentation. However, lobar atrophy, vascular pathology, and Lewy body pathology were similar across the groups, while frontotemporal degeneration with tau pathology was less common in the active seizure group.

These findings highlight that ongoing seizures are associated with more severe neurodegeneration, emphasizing the importance of aggressive seizure management to mitigate neurodegenerative progression.

Authors/Disclosures
Rithvik Gundlapalli
PRESENTER
Mr. Gundlapalli has received research support from University of Virginia School of Medicine.
Jaideep Kapur, MD, PhD (UVA Neurology) The institution of Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Marinus. Dr. Kapur has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Robert Wood Johnson Foundation . Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Kapur has received research support from NIH. Dr. Kapur has received intellectual property interests from a discovery or technology relating to health care. Dr. Kapur has a non-compensated relationship as a Chair, Board North America with International League against Epilepsy that is relevant to AAN interests or activities. Dr. Kapur has a non-compensated relationship as a Board of Directors with American Epilepsy Society that is relevant to AAN interests or activities.
Carol A. Manning, PhD The institution of Dr. Manning has received research support from Department of Defense.
Prachi T. Parikh, MD (Cleveland Clinic) Dr. Parikh has nothing to disclose.
Mark S. Quigg, MD (UVA Neurology) Dr. Quigg has received personal compensation for serving as an employee of Natus. Dr. Quigg has received personal compensation for serving as an employee of Neurocrine. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Finnigen and Harrison. Dr. Quigg has received research support from NIH. Dr. Quigg has received publishing royalties from a publication relating to health care.
Ifrah Zawar, MD (Cleveland Clinic) The institution of Dr. Zawar has received research support from Alzheimer's association. The institution of Dr. Zawar has received research support from American epilepsy society .